Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Did targeted therapy fail cyclooxygenase too?

× No keyword cloud information.

4 in total

1. Celecoxib With Neoadjuvant Chemotherapy for Breast Cancer Might Worsen Outcomes Differentially by COX-2 Expression and ER Status: Exploratory Analysis of the REMAGUS02 Trial.

Authors: Anne-Sophie Hamy; Sandrine Tury; Xiaofei Wang; Junheng Gao; Jean-Yves Pierga; Sylvie Giacchetti; Etienne Brain; Barbara Pistilli; Michel Marty; Marc Espié; Gabriel Benchimol; Enora Laas; Marick Laé; Bernard Asselain; Brice Aouchiche; Martin Edelman; Fabien Reyal
Journal: J Clin Oncol Date: 2019-01-31 Impact factor: 44.544

2. Phase II study of celecoxib and docetaxel in non-small cell lung cancer (NSCLC) patients with progression after platinum-based therapy.

Authors: Bryan J Schneider; Gregory P Kalemkerian; Michael J Kraut; Antoinette J Wozniak; Francis P Worden; Daryn W Smith; Wei Chen; Shirish M Gadgeel
Journal: J Thorac Oncol Date: 2008-12 Impact factor: 15.609

3. Phase II study of docetaxel and celecoxib, a cyclooxygenase-2 inhibitor, in elderly or poor performance status (PS2) patients with advanced non-small cell lung cancer.

Authors: Shirish M Gadgeel; Antoinette Wozniak; John C Ruckdeschel; Lance K Heilbrun; Raghu Venkatramanamoorthy; Ruth A Chaplen; Michael J Kraut; Gregory P Kalemkerian
Journal: J Thorac Oncol Date: 2008-11 Impact factor: 15.609

4. A randomized, placebo-controlled, multicenter, biomarker-selected, phase 2 study of apricoxib in combination with erlotinib in patients with advanced non-small-cell lung cancer.

Authors: Barbara J Gitlitz; Eric Bernstein; Edgardo S Santos; Greg A Otterson; Ginger Milne; Mary Syto; Francis Burrows; Sara Zaknoen
Journal: J Thorac Oncol Date: 2014-04 Impact factor: 15.609

4 in total